Dr. I-Shu Lee received his Ph.D. in Biology from the University of Kassel, Germany, and has participated in research projects at Heidelberg University and Academia Sinica. With more than 20 years of experience in the biotechnology industry, his expertise spans technology development, business strategy, and scientific consulting.

He leads the development and commercialization of Vitae Biomedical’s non-invasive diagnostic technologies, including the company’s urine-based lung cancer risk assessment platform. Under his leadership, Vitae Biomedical has established a clinical testing service model and expanded collaborations with healthcare institutions and international partners.

Dr. Lee currently oversees corporate strategy, R&D planning, project management, fundraising initiatives, and international business development, driving the company’s transition from research innovation toward scalable clinical implementation.